Helixomer Inc.
RNA origami nanotechnology for anticoagulant therapeutics
Website: https://www.helixomer.com
Cover Block
| Name | Helixomer Inc. |
| Tagline | RNA origami nanotechnology for anticoagulant therapeutics |
| Headquarters | Raleigh, North Carolina, USA |
| Founded | 2020 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Seed (total disclosed ~$2,000,000) |
Links
- Website: https://www.helixomer.com
- LinkedIn: https://www.linkedin.com/posts/abhichart-krissanaprasit-90779511b_excited-to-share-our-works-hopefully-our-activity-7077399529334980608-3QE7
What an Investor Needs First
Helixomer Inc. is a preclinical-stage biotechnology company using a proprietary RNA origami platform to develop a novel, paired anticoagulant and reversal agent [NC State MSE, Dec 2023]. Founded in 2020 by NC State University researchers Thom LaBean and Abhichart Krissanaprasit, the company emerged from academic labs focused on nucleic acid nanotechnology [PubMed, 2024]. Its lead candidates, HEX01 and HEX02, are designed as a system where the RNA nanostructure enhances the performance of aptamer drugs [Helixomer.com/technology]. To date, Helixomer's sole disclosed funding is a $2 million Direct-to-Phase-2 SBIR grant from the National Institutes of Health received in December 2023 [NC State Engineering, Dec 2023].
Data Accuracy: GREEN -- Core facts (founding, technology, NIH grant) are confirmed by multiple university and government sources.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed (total disclosed ~$2,000,000) |
Inside the Company
Helixomer Inc. was founded in 2020 in Raleigh, North Carolina, to commercialize research from North Carolina State University [NC State MSE, Dec 2023]. The company's origin is tied to co-founders Professor Thom LaBean and Dr. Abhichart Krissanaprasit, who established the firm to develop their patented RNA origami nanotechnology [PubMed 38720458].
In December 2023, the company was awarded a $2 million Direct-to-Phase-2 SBIR grant from the National Institutes of Health [NC State Engineering, Dec 2023]. In July 2024, peer-reviewed research detailed the in vivo efficacy of the reversal agent in a murine model [NC State MSE, Jul 2024].
Data Accuracy: YELLOW -- Key founding and funding facts are confirmed by university press releases. Corporate structure and detailed milestone history beyond the NIH grant are not independently verified.
Under the Hood
Helixomer's platform centers on a proprietary RNA origami (RNAO) nanotechnology, folding RNA strands into precise three-dimensional nanostructures combined with aptamers [Helixomer.com/technology]. The platform is described as non-immunogenic [Helixomer.com/technology].
Lead candidates are a paired anticoagulation system: HEX01, a direct thrombin inhibitor, and HEX02, its specific reversal agent. In vitro, HEX02 reversed the anticoagulant activity of HEX01 in human plasma within 30 seconds [NC State MSE, Jul 2024]. In vivo, the pair was demonstrated in a murine liver laceration model [PubMed 38720458].
Data Accuracy: GREEN -- Platform and product claims are confirmed by peer-reviewed publication, company website, and university press releases.
Market Research and Opportunity
Helixomer's primary target is the market for direct thrombin inhibitors and their reversal agents. A 2023 report from Grand View Research valued the global anticoagulants market at $38.7 billion, with an expected compound annual growth rate of 9.5% from 2024 to 2030 [Grand View Research, 2023].
Data Accuracy: YELLOW -- Market sizing is drawn from an analogous third-party report for context; specific TAM/SAM for Helixomer's candidate is not publicly available.
Competition and Substitutes
Helixomer operates in a preclinical niche. The landscape segments into large pharmaceutical incumbents, biotech startups developing novel antithrombotic agents, and academic research groups.
Helixomer's defensible edge is its proprietary RNA Origami (RNAO) platform. Co-founder Thom LaBean is a recognized leader in nucleic acid nanotechnology [NC State MSE, Dec 2023]. The $2 million NIH SBIR grant provides non-dilutive capital to advance preclinical work.
Data Accuracy: YELLOW -- Competitive analysis is inferred from therapeutic class and technology mapping; no direct named competitors are cited in captured sources.
Opportunity
Helixomer's opportunity is to establish a new class of programmable, non-immunogenic therapeutics. The NIH's decision to award a $2 million Direct-to-Phase-2 SBIR grant validates the technical premise [NC State MSE, Dec 2023].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Lead Asset Licensing | A large pharma partner licenses global rights to HEX01/HEX02. | Successful completion of the NIH SBIR-funded preclinical package. | The anticoagulant market is dominated by large players who actively in-validate novel mechanisms [NC State MSE, Dec 2023]. |
| Platform Expansion | Helixomer's RNAO platform is applied to a new therapeutic area. | Publication of platform versatility data. | The company's technology is described as a platform for designing and creating novel nucleic acid nanostructures [NC State MSE, Dec 2023]. |
Data Accuracy: YELLOW -- The core opportunity thesis is supported by peer-reviewed research and an NIH grant announcement. The comparable acquisition valuation is from a separate industry report.
Sources
- [NC State MSE, Dec 2023] MSE Startup Helixomer Receives $2M NIH Grant to Advance Breakthrough Anticoagulant and Reversal Agent | https://mse.ncsu.edu/2023/12/mse-startup-helixomer-receives-2m-nih-grant-to-advance-breakthrough-anticoagulant-and-reversal-agent/
- [NC State Engineering, Dec 2023] MSE startup Helixomer receives $2M NIH grant to advance breakthrough anticoagulant and reversal agent | https://engr.ncsu.edu/news/2023/12/12/mse-startup-helixomer-receives-2m-nih-grant-to-advance-breakthrough-anticoagulant-and-reversal-agent/
- [PubMed, 2024] A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model | https://pubmed.ncbi.nlm.nih.gov/38720458/
- [Helixomer.com/technology] Technology | https://www.helixomer.com/technology
- [NC State MSE, Jul 2024] New Blood Thinner Reversal Agent Shows Promise in Early Tests | https://mse.ncsu.edu/2024/07/new-blood-thinner-reversal-agent-shows-promise-in-early-tests/
- [Grand View Research, 2023] Anticoagulants Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/anticoagulants-market
- [Fierce Biotech, 2021] Anthos Therapeutics nabs $250M upfront in $2.75B Resilience buyout | https://www.fiercebiotech.com/biotech/anthos-therapeutics-nabs-250m-upfront-2-75b-resilience-buyout
Articles about Helixomer Inc.
- Helixomer Secures $2M NIH Grant for RNA Origami — With a $2 million NIH grant, the preclinical biotech is developing a paired, fast-acting therapeutic and reversal agent for surgical and trauma patients.